Gilead’s Yeztugo, a long-acting HIV capsid inhibitor, shows 96 to 100% efficacy in phase 3 trials and aims to expand access worldwide through regulatory filings and support programs.
A coalition of over 100 US companies is supporting the federal initiative to end the HIV epidemic by 2030, but legal and funding threats now jeopardize this progress and the significant health and economic benefits it promises.